When was MedKairos founded?

MedKairos was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is MedKairos located?

MedKairos is headquartered in Ann Arbor, United States.

Who is the current CEO of MedKairos?

Michael Moore of MedKairos. They have also founded 1 company.

Is MedKairos a funded company?

MedKairos is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 13, 2018.

When was the latest funding round of MedKairos?

MedKairos' latest funding was a $***** Seed round on Aug 13, 2018, with participation from 0 investor. Its primary sector is Healthcare IT. In United States, the Healthcare IT sector has seen $4.43B in funding in 2026 to date.

Where does MedKairos rank among its competitors?

MedKairos ranks 11th amongst 29 active competitors, of which 9 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Nanovery, which secured $1.47M in Apr, 2025.

Who are the top competitors of MedKairos?

MedKairos' top competitors include Prenuvo, IdentifySensors and Nanovery. Among them, Nanovery secured the most recent funding round in April, 2025.

MedKairos - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of biopsy system to automate the cancer biopsy process. The company has developed a medical device known as the Bioptic system that integrate machine learning and microfluidics technology to increase the accuracy of cancer sample collection and enhance clinical decision-making.

Website: medkairos.com
Social
Email ID: *****@medkairos.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Ann Arbor, United States

Stage

Seed

Total Funding

$365K in 1 round

Latest Funding Round

Seed, Aug 13, 2018, $*****

Investors

TusStar Ann Arbor & 1 more

Ranked

11^th among 29 active competitors

Similar Companies

Prenuvo & 30 more

View MedKairos' full profile

MedKairos has raised a total funding of $365K over 1 round. MedKairos has 2 institutional investors.

Here is the list of recent funding rounds of MedKairos:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 13, 2018	8683142	Seed	1292891	2047619	4067898	1356692

Access funding benchmarks and valuations. Sign up today!

View details of MedKairos's funding rounds and investors

The founders of MedKairos is Michael Moore. Michael Moore is the CEO of MedKairos.

Here are the details of MedKairos' key team members:

Michael Moore: Founder & CEO of MedKairos and founder of 1 other company.
Contact Info: 1 email address

View details of MedKairos's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MedKairos include Prenuvo, IdentifySensors and Nanovery. Here is the list of Top 10 competitors of MedKairos, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Prenuvo 2018, San Francisco (United States), Series C	Provider of MRI and other screening services	$275M	Forerunner Ventures, Felicis Ventures & 10 others	57/100
2nd	IdentifySensors 2006, Shaker Heights (United States), Series B	Provider of bio-sensors for real-time detection of materials and chemicals harmful to humans	$22.1M	-	51/100
3rd	Nanovery 2018, London (United Kingdom), Seed	Developer of nanobots for diagnosing cancer	$7.32M	prostate-cancer-research.org.uk, Earlymarket ... & 11 others	47/100
4th	C the Signs 2016, London (United Kingdom), Series A	Platform offering cancer prediction system for early cancer detection	$14.9M	Khosla Ventures, Mainspring Fund Services	43/100
5th	inveox 2017, Munich (Germany), Series A	Manufacturing automated laboratory solutions for biopsy sample preparation	$25.8M	Kacu Systemic, Startup Creasphere & 7 others	41/100
6th	Pathware 2003, Seattle (United States), Series A	Developer of cloud-based imaging and sample management platform	$8.46M	UnityPoint Health Ventures, Level Eight Ventures ... & 14 others	41/100
7th	Thynk Health 2014, Lexington (United States), Acquired	Provider of lung cancer screening platform	$2.49M	Bluegrass Angels, Global Equity Ventures & 1 others	41/100
8th	WittGenBiotechnologies 2023, Berkeley (United States), Seed	AI-driven software for single-cell RNA sequencing cancer test analysis	$180K	-	33/100
9th	Owl Peak Technologies 2019, Charlottesville (United States), Unfunded	Platform offering solutions for early cancer detection through imaging and ML technology	-	-	30/100
10th	Insight Medbotics 2017, Hamilton (Canada), Seed	Breast cancer diagnosis and decision-making device for the healthcare professional	$435K	McMaster University	28/100
11th	MedKairos 2017, Ann Arbor (United States), Seed	Developer of biopsy system to automate the cancer biopsy process	$365K	TusStar Ann Arbor, Valley Venture Mentors	27/100